Assembly Biosciences, Inc. (ASMB) formed double top with $47.59 target or 5.00% above today’s $45.32 share price. Assembly Biosciences, Inc. (ASMB) has $912.32 million valuation. The stock increased 5.76% or $2.47 during the last trading session, reaching $45.32. About 140,451 shares traded. Assembly Biosciences, Inc. (NASDAQ:ASMB) has risen 353.70% since February 13, 2017 and is uptrending. It has outperformed by 337.00% the S&P500.
The stock increased 0.34% or $0.04 during the last trading session, reaching $11.84. About 126,640 shares traded or 35.83% up from the average. Putnam Municipal Opportunities Trust (PMO) has declined 3.49% since February 13, 2017 and is downtrending. It has underperformed by 20.19% the S&P500.
Among 3 analysts covering Assembly Biosciences (NASDAQ:ASMB), 1 have Buy rating, 0 Sell and 2 Hold. Therefore 33% are positive. Assembly Biosciences had 3 analyst reports since November 8, 2017 according to SRatingsIntel.
Analysts await Assembly Biosciences, Inc. (NASDAQ:ASMB) to report earnings on March, 1. After $-0.71 actual earnings per share reported by Assembly Biosciences, Inc. for the previous quarter, Wall Street now forecasts 11.27% negative EPS growth.
Robinson Capital Management Llc holds 3.1% of its portfolio in Putnam Municipal Opportunities Trust for 547,264 shares. Mackay Shields Llc owns 1.23 million shares or 0.58% of their US portfolio. Moreover, Brave Asset Management Inc has 0.35% invested in the company for 52,431 shares. The Illinois-based Goodwin Daniel L has invested 0.32% in the stock. Twin Focus Capital Partners Llc, a Massachusetts-based fund reported 31,294 shares.